PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Efforts to curb hospital readmissions take center stage

Studies focus on identifying vulnerable patients, early follow up, medication and engagement

2014-03-31
(Press-News.org) WASHINGTON (March 29, 2014) — Strategies aimed at reducing the number of patients with heart failure and other cardiovascular conditions who find themselves back in the hospital after discharge were identified in six new studies presented at the American College of Cardiology's 63rd Annual Scientific Session.

One out of five Medicare patients with heart failure is readmitted to the hospital within just one month of discharge, a fact that is not only bad news for patients who would most likely prefer to avoid another hospital stay, but it also places intense economic pressures on hospitals and the health care system as a whole, especially amid new federally imposed reimbursement cuts related to readmissions.

"It is important to patients that they be able to remain at home after they are discharged," said Mary Norine Walsh, M.D., FACC, medical director of the Heart Failure and Cardiac Transplant Program at St. Vincent's Heart Center of Indiana and chair of the American College of Cardiology Care Transition Leadership Group. "But the real driving force for hospitals to reduce readmissions has come with the Affordable Care Act ruling that financially penalizes hospitals for unnecessary readmissions within 30 days after hospital discharge for key diagnoses, including heart failure."

Hospitals are projected to lose billions in reimbursement dollars for higher than average 30-day all-cause readmissions. Heart failure affects 6.5 million American adults and it is on the rise. It is the leading cause of hospitalization among people aged 65 and older.

The American College of Cardiology has been championing quality improvement efforts to help clinicians and hospitals lower readmissions rates through participation in its Hospital to Home Quality Initiative and Patient Navigator Program. For more and more hospitals and health systems, strategies that help prevent readmissions for any cause are a needed support tool. Research has shown that patient education about heart failure, including what to do when faced with worsening symptoms, and early follow-up (within seven days of discharge) work.

"Finding innovative ways to identify patients who are more likely to be readmitted post-discharge – while they are still under our care in the hospital – can help clinicians deliver more targeted strategies for these high risk patients," Walsh said.

Six studies were highlighted in a press conference moderated by Walsh today at the ACC's 63rd Annual Scientific Session:

Starting Patients on an ACE inhibitor or ARB Prior to Discharge Cuts 30-Day Readmissions In a retrospective study of 1,348 hospitalized Medicare beneficiaries with acute heart failure and an ejection fraction of less than 45 percent, researchers at the University of Alabama at Birmingham found that patients who were started on an angiotensin converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blockers (ARB) prior to discharge had significantly lower 30-day all-cause readmission, 30-day heart failure readmission and 30-day all-cause mortality compared with those who were not offered these drugs.

24 percent of patients who did not receive these drugs were readmitted within 30 days of hospital discharge for any cause compared with 18 percent of those who were started on these medications. The rate of 30-day heart failure readmissions was nearly halved – with 14 percent of those who did not receive an ACE inhibitor or ARB being readmitted compared to just 7 percent of those who did. Senior study author Ali Ahmed, M.D., M.P.H., said the results demonstrate that the use of evidence-based guideline-recommended therapy for patients without contraindications could significantly lower the risk of 30-day all-cause readmissions, "an important contemporary outcome with financial implications for hospitals."

Study of 2.5 Million Identifies Patients Most Likely to Return to the Hospital Researchers at Western Michigan School of Medicine identified more than 2.5 million admissions for chronic heart failure at hospitals nationwide with a total 30-day readmission rate of nearly 25 percent. The analysis offers new insight into demographic risk factors that may make certain patients more likely to be readmitted to the hospital within 30 days of discharge. Young males and patients covered under Medicaid were associated with higher readmission rates with heart failure as a primary cause, while older patients and women were associated with higher readmission rates from other causes. Researchers conclude that strategies to reduce readmissions should focus on chronic heart failure in patients who are young, male and covered by Medicaid and on managing other risk factors, such as infection, kidney injury and other issues, for older patients and women.

Lead study author Sourabh Aggarwal, M.D., said this is the largest study to date looking at heart failure readmissions for specific susceptible populations. Researchers were unable to account for the potential contribution of other comorbidities to readmission.

Automated Tool Predicts Individual's 30-Day Risk of Readmission A risk stratification formula that uses information already collected as part of patients' electronic medical record can predict the risk of 30-day readmissions and may allow for earlier intervention for high-risk patients, according to researchers.

The tool, called the Providence Vulnerability Index, was developed and validated by researchers at Providence Health and Services, a large health system operating in five western states. Researchers studied records of 30,252 patients with heart failure admitted to seven hospitals across four states between October 2012 and September 2013.

The index included and assigned points to personal variables such as medical history including other comorbidities, number of hospitalizations within the past 90 days, substance abuse and psychiatric disorders. The index ranges from a score of one (very low risk) to six (very high risk), which correlates with a 4 to 39 percent predicted risk of 30-day readmission.

Lead author Alicia M. Ross, M.D., said "we believe that the use of this model will allow us to provide early interventions prior to discharge, tailored to a patient's risk for readmission." She also said this tool is complementary to others, explaining its strength is its use of data obtained at admission in a standard EMR and its ability to allow clinicians to easily identify those variables that are driving an individual's risk.

Simple Test to Screen for Cognitive Impairment May Also Predict 30-Day Readmission and Death Patients who performed poorly on a simple, three-minute memory and executive functioning test had worse post-discharge outcomes than those who performed well. Heart failure patients who were cognitively impaired were also two times more likely to be rehospitalized or die. This is the first study to evaluate the "Mini-Cog" test, which involves asking a patient to memorize three unrelated words, draw a clock as a distractor and recall the three words. The test is scored from zero to five based on a composite performance of these tasks, with a score of less than or equal to two indicating a high likelihood of cognitive impairment.

In this single-center prospective study of 720 patients, researchers at Cleveland Clinic found that nearly one in four patients hospitalized for heart failure who completed the Mini-Cog assessment had a high-likelihood of cognitive impairment. Patients with a high likelihood of cognitive impairment had a higher rate of 30-day all-cause readmissions or death compared with those with a low likelihood of cognitive impairment (47 percent compared to 22 percent).

Data showed that the destination of discharge modified the relation between patients' performance on the Mini-Cog and outcomes. Those who were discharged to a facility like a nursing home had a longer time to readmission or death compared with patients who returned home. Lead author Eiran Gorodeski, M.D., said this may mean that "routine interventions such as heart failure education may be less relevant in patients with cognitive impairment, while decisions regarding type of community-based care delivery may be more important."

Earlier studies have shown cognitive deficits are common in patients with heart failure, and that these patients have poorer adherence to treatment, are less able to perform activities of daily living and have worse self-care overall. While published guidelines recommend screening for cognitive impairment in this population, Gorodeski said they do not identify how. "We believe that practitioners caring for patients hospitalized with heart failure should incorporate the Mini-Cog testing into their routine clinical care, especially prior to hospital discharge."

Smartphone-Based App Helps Patients Stay Out of the Hospital Post-PCI Patients who used an online/smartphone-based program to track and participate in their recovery in addition to participating in cardiac rehabilitation had greater improvements in cardiovascular risk factors and were less likely to be readmitted to the hospital within 90 days of discharge compared with those who underwent cardiac rehab alone. In fact, patients using the app were 40 percent less likely to be readmitted to the hospital – with only 20 percent returning to the hospital compared to 60 percent of those in the control group. Patients using the app-based intervention also had significantly greater reductions in body weight and blood pressure compared to controls.

In this small study, 44 patients at Mayo Clinic who were hospitalized after having a stent placed following a heart attack were divided into two groups – one which received cardiac rehab alone and the other cardiac rehab plus a virtual personal health assistant. The 25 patients using the online program were asked to monitor and record their own blood pressure, weight, cholesterol and blood sugar levels, minutes of physical activity as well as dietary habits at baseline and daily throughout the study. They were also encouraged to undertake certain educational tasks, which instructed them on guideline-based lifestyle changes to support their heart health. Changes in risk factors and re-hospitalizations/visits to the emergency department were assessed after three months.

Senior author Amir Lerman, M.D., said the data provide evidence that this program can augment usual cardiac rehabilitation to improve risk factors and reduce the health care burden of repeat cardiovascular events. Additional research will look at the means by which this intervention was successful in reducing rehospitalizations, whether through improved surrogate markers of cardiovascular disease, additional education, increased connectivity to the health system or other factors. Patients received no external or monetary award for using the self-directed online program.

Performance Improvement Initiative Boosts Timely Follow Up After Discharge Early follow-up after hospitalization for heart failure – within seven days of discharge – has been linked to a lower likelihood of being readmitted. The trick is getting patients to schedule and keep these outpatient appointments. A new study found that implementing a coordinated, heart failure performance improvement initiative in an integrated delivery system may significantly improve the rate of scheduling and following through with these post-discharge visits.

At Kaiser Permanente of Georgia, 273 heart failure patients who were discharged after this program was formally rolled out were compared against 224 patients who received hospital care before the program was instituted. The post-initiative group was 65 percent more likely than the pre-initiative group to have a scheduled follow-up appointment within seven days (78.4 percent compared to 47.5 percent) and 34 percent more likely within 14 days (94.3 percent compared to 70.2 percent) of discharge. Similarly, there was an increase in the rate of appointments completed within seven and 14 days – 33.5 percent of the pre-initiative group were seen within seven days compared with 60.8 percent of the post-initiative group; only half of patients in the pre-initiative group were seen within 14 days compared with 80.6 percent of those after the performance improvement effort was in place.

This initiative engaged inpatient and outpatient care delivery teams across this integrated health system. A heart failure discharge planner was created, which captured patient information, diagnosis, core measures including medications and ejection fraction, inpatient education, discharge weight, patient barriers and lastly the outpatient follow-up appointment within seven days.

"To improve the outcome measure of 30-day all-cause readmission rates post-hospital discharge, we must first improve the various processes affecting the care of the patient," said Ali Rahimi, M.D., lead author of the study. "This includes a coordinated multi-disciplinary team effort along the continuum of inpatient to outpatient care. An integrated health care system may allow for more effective implementation of such performance improvement initiatives."

INFORMATION: The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC14 for the latest news from the meeting.

The American College of Cardiology is a nonprofit medical society comprised of 47,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formulation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit CardioSource.org.


ELSE PRESS RELEASES FROM THIS DATE:

Primary cardiovascular disease prevention is leaving the office

2014-03-31
MINNEAPOLIS, MN – March 30, 2014 – Early results from HeartBeat Connections, a telemedicine program supported by the Minneapolis Heart Institute Foundation (MHIF), suggest effective primary prevention for cardiovascular disease (CVD) may be achieved with a team-based approach that integrates office visits with supplemental phone coaching. HeartBeat Connections provides dietitian- and nurse-led coaching over the phone to adults at high risk for CVD, with the goal of helping to improve and control key CVD risk factors. Gretchen Benson, RD, CDE, Healthcare Systems Integration ...

Adults with inherited high cholesterol are underdiagnosed and undertreated

2014-03-31
MINNEAPOLIS, MN – March 30, 2014 – An estimated 1 in 500 people worldwide suffer from familial hypercholesterolaemia (FH), an inherited condition of extremely high cholesterol that is associated with premature heart disease and death. Despite this high prevalence, recent research funded by the Minneapolis Heart Institute Foundation (MHIF) confirms FH is underdiagnosed and undertreated. Thomas Knickelbine, MD, Preventive Cardiology Director at the Minneapolis Heart Institute at Abbott Northwestern Hospital, will present the results of research aimed at identifying just ...

Evolocumab superior to ezetimibe in lowering LDL cholesterol

2014-03-31
WASHINGTON (March 30, 2014) — Evolocumab, an injected form of a class of drugs called PCSK9 inhibitors that lower low-density lipoprotein cholesterol, also known as LDL-C or "bad cholesterol," outperformed ezetimibe with few side effects in patients unable to take statins, according to research from GAUSS-2 presented at the American College of Cardiology's 63rd Annual Scientific Session. High LDL cholesterol is considered a major risk factor for cardiovascular disease. Statins are commonly prescribed to reduce that risk. Currently ezetimibe is one of the few options ...

Head-to-head study favors balloon-expandable transcatheter heart valves

2014-03-31
WASHINGTON (March 30, 2014) — A first-ever randomized head-to-head comparison of two devices commonly used to treat the age-related disease aortic stenosis finds balloon-expandable transcatheter valves result in more successful procedures and relieve symptoms more frequently than self-expanding valves, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. Aortic stenosis is a condition in which a crucial valve in the heart ceases to function properly. The only cure is to replace the valve, either through open heart surgery ...

Higher risks without cardio benefits halt study of aleglitazar

2014-03-31
WASHINGTON (March 30, 2014) — The phase III AleCardio trial was ended early when patients with type 2 diabetes and recent acute coronary syndrome who were treated with aleglitazar showed higher rates of heart failure, kidney events and gastrointestinal bleeding with no offsetting cardiovascular benefits, according to data presented at the American College of Cardiology's 63rd Annual Scientific Session. All other studies with the drug have been stopped as well. Aleglitazar sparked interest for this patient population because of its dual action on two subtypes of the PPAR ...

Darapladib falls short in chronic coronary heart disease

2014-03-31
WASHINGTON (March 30, 2014) — The novel inflammation inhibitor darapladib showed no primary-endpoint advantage over placebo in patients with chronic coronary heart disease treated with a high level of background care, although it did suggest possible benefits for more specific coronary artery-related endpoints, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. STABILITY is the first study to test this inflammation-prevention mechanism for reducing the likelihood that plaque will become an artery-blocking clot. Darapladib ...

Evolocumab safely drops LDL cholesterol well below statin-only baseline

2014-03-31
WASHINGTON (March 30, 2014) — The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein (LDL) cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to data from the LAPLACE-2 study presented at the American College of Cardiology's 63rd Annual Scientific Session. LDL cholesterol is considered a major risk factor for cardiovascular disease. "High-risk patients – such as those with clinical cardiovascular disease, high LDL cholesterol levels or diabetes – are ideally treated with high-intensity ...

Anti-gout medication colchicine helps patients with recurrent pericarditis

2014-03-31
WASHINGTON (March 30, 2014) — A medication traditionally used to treat gout is also effective at treating recurrent pericarditis, an inflammation of the sac-like covering around the heart, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. In the first multicenter, double-blind trial to look at the use of colchicine for multiple recurrences of pericarditis, 240 patients were randomly assigned to either the study drug or placebo to examine the primary endpoint of recurrent pericarditis. The rate of disease recurrence ...

Renal denervation patient registry finds low rate of adverse events

2014-03-31
WASHINGTON (March 30, 2014) — Patients with uncontrolled high blood pressure treated with renal denervation had low rates of adverse events and significant lowering of blood pressure at six months, according to a registry-based study presented at the American College of Cardiology's 63rd Annual Scientific Session. The Global SYMPLICITY Registry is the first and largest dataset of patients with uncontrolled hypertension treated with renal denervation. The open-label, multicenter study was established to examine the safety and effectiveness of the procedure. Outcomes presented ...

Post-approval study of transcatheter pulmonary valve completes 1 year

2014-03-31
WASHINGTON (March 30, 2014) — The first post-FDA approval study of a non-surgically implanted replacement pulmonary valve showed strong short- and mid-term results for the device in a small sample of patients with certain congenital heart defects, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. This multi-center study of 100 patients consecutively implanted with the Melody transcatheter pulmonary valve between July 2010 and July 2012 assessed the effectiveness of the device at six and 12 months based on the percentage ...

LAST 30 PRESS RELEASES:

Animated movie characters with strabismus are more likely to be villains, study finds

How retailers change ordering strategy when a supplier starts its own direct channel

Young coral use metabolic tricks to resist bleaching

Protecting tax whistleblowers pays off

Bioluminescent proteins made from scratch enable non-invasive, multi-functional biological imaging

New study links air pollution with higher rates of head and neck cancer

LSU researchers excavate earliest ancient Maya salt works

Building a diverse wildland fire workforce to meet future challenges

MBARI researchers discover remarkable new swimming sea slug in the deep sea

Decentralized social media ‘increases citizen empowerment’, says Oxford study

Validating an electronic frailty index in a national health system

Combination approach shows promise for treating rare, aggressive cancers

Raise the roof: How to reduce badminton birdie drift

Ouch! Commonalties found in pain vocalizations and interjections across cultures

Income-related disparities in mortality among young adults with type 2 diabetes

Medical board discipline of physicians for spreading medical misinformation

First-ever randomized clinical trial uses telehealth for suicide prevention

DNA packaging directly affects how fast DNA is copied in cells

Scientists develop advanced catalyst for self-driven seawater splitting with enhanced chloride resistance

City of Hope researchers discover why taking a mushroom supplement slows or prevents prostate cancer from getting worse

Montefiore Einstein’s Marina Konopleva joins Break Through Cancer TeamLab in fight against acute myelogenous leukemia

Early treatment for nerve tumors prevents serious problems, study finds

Study: Student absenteeism crisis may be hurting teacher job satisfaction

Medicaid enrollment continuity tied to lymphoma stage at diagnosis

INSEAD launches free Negotiation Course for the World

Wyss Institute’s iNodes team receives ARPA-H Sprint for Women’s Health award to advance the first implantable immune organs to treat ovarian cancer

Goblet cells could be the guardians of the gut

Romania’s science journalists join forces on new reporting handbook 

SwRI-led team proposes new solar composition ratios that could reconcile longstanding questions

Sodium butyrate inhibits necroptosis by regulating MLKL via E2F1 in intestinal epithelial cells of liver cirrhosis

[Press-News.org] Efforts to curb hospital readmissions take center stage
Studies focus on identifying vulnerable patients, early follow up, medication and engagement